[{"orgOrder":0,"company":"Asarina Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Allopregnanolone","moa":"steroids (not prednisolone derivatives)","graph1":"Neurology","graph2":"Phase II","graph3":"Asarina Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Asarina Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Asarina Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Asarina Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Allopregnanolone","moa":"GABA-A receptor; anion channel","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Asarina Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Asarina Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Asarina Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Asarina Pharma","sponsor":"Relmada Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Allopregnanolone","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase II","graph3":"Asarina Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Asarina Pharma \/ Relmada Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Asarina Pharma \/ Relmada Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Asarina Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Relmada acquires Isoallopregnanolone (sepranolone) from Asarina. Sepranolone is a first-in-class GABAA Modulating Steroid Antagonist (GAMSA), being evaluated for Tourette syndrome.

                          Product Name : Isoallopregnanolone

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          February 06, 2025

                          Lead Product(s) : Allopregnanolone

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Relmada Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          02

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 28, 2022

                          Lead Product(s) : Allopregnanolone

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Substantial reduction in PMDD symptoms was achieved across the patient population, but, in comparison to placebo, primary and secondary endpoints were not statistically significant.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 21, 2020

                          Lead Product(s) : Allopregnanolone

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 25, 2019

                          Lead Product(s) : Allopregnanolone

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Aurevia

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 05, 2018

                          Lead Product(s) : Allopregnanolone

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase II

                          Sponsor : Ergomed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank